FDA Inspection 1130514 — Christopher van Dyck, M.D.
The FDA completed an inspection of Christopher van Dyck, M.D. on September 10, 2020 in New Haven, CT. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- September 10, 2020
- Fiscal Year
- 2020
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- New Haven, CT (United States)
Additional Details
Clinical Investigator (CI)